Evidence map›Paper›PMID 34748551›Full record

SynthesisPloS one2021

Return of individual research results from genomic research: A systematic review of stakeholder perspectives.

Danya F Vears, Joel T Minion, Stephanie J Roberts, James Cummings, Mavis Machirori, Mwenza Blell, Isabelle Budin-Ljøsne, Lorraine Cowley, Stephanie O M Dyke, Clara Gaff and 8 more

Abstract readSystematic Review
In one paragraph

Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Return of Research Results to Participants in Longitudinal Cohort Studies in Health Research: Findings From 24 Cohorts of the Amsterdam Cohort Hub.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  5. A 360 Degree Qualitative Ethical Assessment of Reporting Patient Reported Outcomes.Journal of empirical research on human research ethics : JERHRE · 2026
    Article
  6. Article
  7. Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Setting.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Research ethics · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Danya F VearsMelbourne Law School, University of Melbourne, Carlton, Australia.ORCID 0000-0002-6290-545X
Joel T MinionPolicy, Ethics and Life Sciences (PEALS) Research Centre, Newcastle University, Newcastle, United Kingdom.
Stephanie J RobertsPolicy, Ethics and Life Sciences (PEALS) Research Centre, Newcastle University, Newcastle, United Kingdom.ORCID 0000-0001-9289-0968
James CummingsSchool of Art, Media and American Studies, University of East Anglia, Norwich, United Kingdom.
Mavis MachiroriPolicy, Ethics and Life Sciences (PEALS) Research Centre, Newcastle University, Newcastle, United Kingdom.
Mwenza BlellPolicy, Ethics and Life Sciences (PEALS) Research Centre, Newcastle University, Newcastle, United Kingdom.ORCID 0000-0002-6794-3826
Isabelle Budin-LjøsneDepartment of Genetics and Bioinformatics, Norwegian Institute of Public Health, Oslo, Norway.
Lorraine CowleyNewcastle upon Tyne NHS Foundation Hospitals Trust, Northern Genetics Service, Centre for Life, Newcastle, United Kingdom.ORCID 0000-0001-7789-5197
Stephanie O M DykeMcGill Centre for Integrative Neuroscience, Montreal Neurological Institute, Department of Neurology & Neurosurgery, McGill University, Montreal, Canada.
Clara GaffMurdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Australia.
Robert GreenHarvard Medical School, Boston, Massachusetts, United States of America.
Alison HallPHG Foundation, University of Cambridge, Cambridge, United Kingdom.
Amber L JohnsCancer Division, Garvan Institute of Medical Research, Sydney, Australia.
Bartha M KnoppersCentre of Genomics and Policy, McGill University, Montreal, Canada.
Stephanie MulrineNorthumbria University, Newcastle, United Kingdom.
Christine PatchGenomics England, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-4191-0663
Eva WinklerNational Center for Tumour Diseases (NCT), Section of Translational Medical Ethics, University of Heidelberg, Heidelberg, Germany.
Madeleine J MurtaghUniversity of Glasgow, Glasgow, United Kingdom.

Funding

Return of Genomic Results and Estimating Penetrance in Population-Based CohortsR01HL143295 · NHLBI · BROAD INSTITUTE, INC. · PI CARSON, APRIL P, GREEN, ROBERT C. · 2019 to 2022
$7.2M
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy InfantsU01TR003201 · NCATS · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C., HOLM, INGRID ADELE · 2021 to 2024
$5.1M
CIHRMedical Research Council MR/N01104X/1Medical Research Council MR/N01104X/2NCATS NIH HHS U01 TR003201NHLBI NIH HHS R01 HL143295Wellcome Trust 206194Wellcome Trust 213422/Z/18/Z
6 · The paper itself

Abstract

Despite the plethora of empirical studies conducted to date, debate continues about whether and to what extent results should be returned to participants of genomic research. We aimed to systematically review the empirical literature exploring stakeholders' perspectives on return of individual research results (IRR) from genomic research. We examined preferences for receiving or willingness to return IRR, and experiences with either receiving or returning them. The systematic searches were conducted across five major databases in August 2018 and repeated in April 2020, and included studies reporting findings from primary research regardless of method (quantitative, qualitative, mixed). Articles that related to the clinical setting were excluded. Our search identified 221 articles that met our search criteria. This included 118 quantitative, 69 qualitative and 34 mixed methods studies. These articles included a total number of 118,874 stakeholders with research participants (85,270/72%) and members of the general public (40,967/35%) being the largest groups represented. The articles spanned at least 22 different countries with most (144/65%) being from the USA. Most (76%) discussed clinical research projects, rather than biobanks. More than half (58%) gauged views that were hypothetical. We found overwhelming evidence of high interest in return of IRR from potential and actual genomic research participants. There is also a general willingness to provide such results by researchers and health professionals, although they tend to adopt a more cautious stance. While all results are desired to some degree, those that have the potential to change clinical management are generally prioritized by all stakeholders. Professional stakeholders appear more willing to return results that are reliable and clinically relevant than those that are less reliable and lack clinical relevance. The lack of evidence for significant enduring psychological harm and the clear benefits to some research participants suggest that researchers should be returning actionable IRRs to participants.

Indexed as

Biomedical ResearchGenomicsGenome, HumanGenomic MedicineHealth PersonnelHuman GeneticsHumansRisk FactorsStakeholder Participation

Identifiers

PMID34748551
PMCPMC8575249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.